Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

ATOS

Atossa Therapeutics, Inc.

  ( )

Page Views : 609389

vista's key points

  • Atossa is led by Dr. Stephen Quay, MD, PhD. who has invented 7 FDA-approved pharmaceuticals which have helped over 80 million people
  • Atossa's COVID-19 HOPE Treatment Program uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators
  • Atossa's AT-301 Nasal Spray therapy for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus
  • Atossa is developing their proprietary Topical & Oral Endoxifen to both help prevent as well as to treat breast cancer
  • Atossa has raised ~have raised a total ~$131 million to bolster its balance sheet, extend runway, & increase corporate options since Dec. 2020.

company profile

 

vista's view

Atossa has added substantial cash resources that they are seeking to use to “accelerate development of our COVID-19 and breast cancer therapies’”. Atossa has raised ~$110 million now via registered directs since Dec. 2020 including today’s $50M raise. They also have added an additional $21 million to their balance sheet through...

Read More

exclusive content

 

Vista Partners creates exclusive content based on the ongoing research of companies included in the VP Watchlist.

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates